Nottinghamshire Joint Formulary Group Meeting Minutes 9 th October 2014, 2-5pm Room 1, Hawthorne House NG18 4LE
|
|
- Leslie McKenzie
- 5 years ago
- Views:
Transcription
1 Nottinghamshire Joint Formulary Group Meeting Minutes 9 th October 2014, 2-5pm Room 1, Hawthorne House NG18 4LE Present: Steve May (SM) Chief Pharmacist, SFHT (chair); Amanda Rawlings (AR) Prescribing Interface Advisor M&A CCG; Steve Haigh (SH) Pharmacist, SFHT; David Kellock (DK) Consultant (left at 4.30pm), SFHT; James Sutton (JS) and Lynne Kennell (LK) Interface/formulary pharmacists, APC; Tanya Behrendt (TB) Pharmacist, Nottingham City CCG; Esther Gladman (EG) GP, Nottingham City CCG; Debbie Storer (DS), Pharmacist, NUH; Julie Curwood (JC) Community Matron, County Health Partnerships, John Lawton (JL) Pharmacist, Notts HC In attendance: Val Yeung, Consultant Psychiatrist, Notts Healthcare for item 5a; David Lang, preregistration pharmacist, NUH, Mohammed-wasim Gul pre-registration pharmacist, SFH Apologies: Khalid Butt (KB) GP, M&A CCG; Meeta Mallik (MM) Consultant Physician, NUH; Judith Gregory (JG) Pharmacist, NUH; Sachin Jadhav (SJ), Consultant, NUH; Felicity Armitage (FA) GP, Notts City CCG; Jill Theobald (JT) Interface/formulary pharmacist, APC. Agenda item Apologies Declarations of Interest Minutes of previous meeting Matters arising and Action Log Notes Noted (see above). None declared. Were accepted as an accurate record It was noted that completed actions had been removed from the action log and APC actions had been added to the APC action log. Rifaximin NICE TA for hepatic encephalopathy had been suspended following information received from the manufacturer. SH reported that there was increasing usage of rifaximin at SFHT Action: TB to investigate reasons for suspension of NICE TA. SH to investigate reasons for increased usage at SFHT. 5. New applications a) Lisdexamfetamine (Elvanse, Shire) for attention deficit/hyperactivity disorder ADHD. Dr Yeung, the requesting consultant, was in attendance Lisdexamfetamine is a pro-drug of dexamfetamine licensed for children and adolescents aged 6 years and over when response to methylphenidate treatment is considered clinically inadequate. The Elvanse SPC states in adolescents whose symptoms persist into adulthood and who have shown clear benefit from treatment, it may be appropriate to continue treatment into adulthood. A submission has been received from consultant psychiatrists at Notts Healthcare Trust, supported by community paediatricians at SFHT and NUH, for lisdexamfetamine to be available as a second line option (i.e. methylphenidate first line, atomoxetine or lisdexamfetamine second line) in line with its license. Methylphenidate and atomoxetine are currently Amber 1 in Nottinghamshire, whereas dexamfetamine is classified Red. 1 Dr Yeung answered the group s questions related to the product and to shared care arrangements. She highlighted that limited experience had been gained in a small number of patients at NottsHC. The group discussed the potential advantages of this product over dexamfetamine (decreased frequency of administration, associated compliance improvements and lack of school administration issues in children, decreased potential for abuse) and over atomoxetine (decreased time to first response which is potentially
2 linked to its shorter titration regimen). Evidence for lisdexamfetamine is limited to short duration studies, only some of which relate to the licensed place in therapy. It is similar in price to atomoxetine whereas dexamfetamine may be cheaper depending on the dose used. Monitoring requirements and side-effects appear similar to alternative stimulants. Current NICE guidance predates the availability of lisdexamfetamine. EG highlighted reservations in primary care about prescribing medicines for ADHD, in particular with amfetamine based products. Concerns were also raised regarding consistency of monitoring these medicines in general practice, the prescribing of ADHD medications into adulthood, and limited experience with lisdexamfetamine in specialist practice. Based on possible advantages to patients and possible safety advantages the group were minded to recommend lisdexamfetamine for addition to the formulary with an Amber 1 classification. Based on concerns regarding the overall service and shared care agreement currently being discussed, the group felt that further discussions were necessary before this recommendation could be taken to APC. As a result the group recommended a RED classification for lisdexamfetamine for Notts HC trust as an interim, and GREY in other organisations subject to application and funding approvals through other committees. Action: JS/LK to take to APC for ratification Primary care members to canvas opinion from their organisations TB/AR/JL to discuss with commissioners b) Liothyronine for depression Liothyronine is currently classified as Amber 2 for treatment of hypothyroidism only, but is not recommended for this condition by the Royal College of Physicians guidance, and this was discussed under separate agenda item 10. Liothyronine is recommended as an option in treatment resistant depression in the Maudsley and British Association of Psychopharmacology guidelines, and is used by psychiatrists at NottsHC in a small number of patients for this indication. GPs are requested to continue this treatment and monitor those patients who are on it. A request for formal traffic lighting and inclusion in the formulary for this use has been received. A review of the evidence was discussed, although it was acknowledged that there were historical studies that hadn t been included in the review. It was noted that the price of liothyronine had increased significantly since the guidance had been written despite being available generically. Maudsley guidelines recommend thyroid function test monitoring, and when used for hypothyroidism the patient should have a baseline ECG. This indication is not listed in the BNF. Despite there being multiple treatment options for depression, there is some usage in other areas with a shared care agreement in place in one region. Concerns were raised about the appropriateness of prescribing of this drug in general, including indication, who has recommended it and monitoring being undertaken irrespective of indication. Based on the information presented the group we not minded to add liothyronine to the joint formulary, due to limited evidence and lack of proven 2
3 cost-effectiveness. There was the concern that approving liothyronine as specialist use for this indication may legitimise some of the inappropriate prescribing. Action: LK/JL to revise evidence review to include historical studies and bring back to December JFG AR/TB to discuss auditing current patients in primary care c) Beclometasone dipropionate MR tablets (Clipper, Chiesi) for ulcerative colitis Clipper tablets are currently classified as GREY. A recent update to NICE Clinical Guideline for ulcerative colitis recommends this preparation is considered in addition to a high dose oral aminosalicylate to induce remission for adults and children with mild to moderate first presentation of, or inflammatory exacerbation of, left-sided or extensive ulcerative colitis. Prescribing for this recommendation would be off-label. Topical aminosalicylates may also be considered at this step. A submission has been received from a consultant at the Nottingham NHS Treatment Centre supported by specialists at both acute Trusts to add Clipper to the formulary to induce remission as per NICE guidance but only as add on therapy for non-responders to aminosalicylates, in line with the product license. Clipper is not licensed for use in children and young people and therapy cycles of more than four weeks are not recommended. NICE does not recommend use of Clipper as a maintenance therapy. The group discussed that the evidence base for this indication is limited to one small randomised placebo controlled trial and that NICE has recommended further research be undertaken to compare Clipper to oral prednisolone. Low systemic availability of the active metabolite from Clipper is thought to limit the systemic steroid side-effects that would be expected with oral prednisolone. NICE and SMC differ in their assessment of this preparations cost-effectiveness. The group recommended Clipper tablets be added to the formulary for the indication requested in the submission with an Amber 2 (specialist recommendation) classification, based on it being recommended as an option in NICE guidance, and possible benefits to patients in terms of steroid induced side-effects. Action: JS to take to APC for ratification. d) Nadolol (Corgard, Sanofi-Aventis) for Long QT syndrome Nadolol is non-cardioselective beta-blocker with a long half-life licensed for multiple indications including arrhythmias. A submission has been received from consultant cardiologists at NUH for addition of nadolol to the formulary for long QT syndrome. Long acting beta blockers such as propranolol MR or nadolol are recommended as treatments of choice for this condition in European Guidance, but recent evidence has indicated that propranolol may be less effective in a subset of patients with this rare condition. It was discussed that most patients with this rare condition will be under a specialist centre and that there is specialist consensus that nadolol should be available as a first line option. Propranolol MR and nadolol have similar acquisition costs although nadolol is less lipophilic and therefore would be expected to cause fewer CNS side effects such as nightmares. 3
4 The group recommended adding nadolol to the formulary with an Amber 2 (specialist recommendation) classification for treatment of Long QT syndrome only, based on clinical effectiveness compared to existing therapies. 6. Formulary amendments Action: LK to take to APC for ratification. a) Formulary amendments for information were noted. b) Formulary amendments for discussion: The group agreed with the recommendations from the Specialist Formulary Pharmacist with the exception of: Clonazepam liquid Only the 2mg/5ml to be added to reduce the risk of mis-selection errors. Added with caveats regarding alcohol content making the licensed product not suitable for children and care should be taken when switching brands for epilepsy patients. JS/LK to liaise with paediatricians and neurology re clonazepam liquid Levomepromazine 6mg tablets DS requested that it was clarified whether community pharmacists will quarter the 25mg tablets for patients, and whether there are patients on ongoing treatment in primary care as this medicine is anticipated to be used for palliative care. AR/TB to liaise with community pharmacy. AR/TB to liaise with community pharmacy re levomepromazine. AR/TB to obtain epact data re levomepromazine Ceftriaxone and teicoplanin for cellulitis JS to investigate primary care cellulitis pathway and bring to future meeting. JS to investigate primary care cellulitis pathway Glycopyronium tablets Include the 2mg tablets or liquid where necessary (1mg tablets non-formulary not cost-effective) in the formulary. LK to discuss with paediatricians Action: LK to take amendments to APC 7. Horizon scanning c) MHRA and other safety warnings. These were noted with no further action recommended. a) New publications for review The August and September New Drugs Online newsletter and the August and September RDTC newsletters were reviewed. The group agreed with the recommendations made by the SIFP. Action: JS to discuss tiotropium for asthma with specialists and encourage submission if necessary b) NICE new medicines summaries ESMN45, 47 and 48 were reviewed by the SIFP. The group agreed with the recommendations made by the SIFPs. c) NICE unlicensed medicines summaries ESUOM33 was reviewed by the SIFPs. The group agreed with the recommendations made by the SIFPs. d) Miscellaneous publications The group agreed with the recommendations made by the SIFPs with the exception of Fostair NEXThaler which is to be classified as GREY non-formulary no formal assessment. It was felt that the data regarding lung deposition was not sufficient to warrant inclusion in the formulary. Action: LK to take horizon scanning to APC. 8. Safety needles The group agreed that the implementation of European Guidance in this area and risk assessments required were beyond the scope of the JFG. 4
5 This issue has been highlighted to relevant medicines management colleagues in individual organisations for their information and discussion. 9. Asthma Care plan Action: Remove item from agenda AR introduced an asthma self-management plan developed by Mansfield and Ashfield CCG. This document had been developed in response to the nationally recommended document being out of date. However since the development of the local plan, the BTS guidance and the asthma UK asthma management plan have been recently updated. There are versions of this plan on the asthma UK website for adults, children and carers/parents. The group discussed the asthma UK versions and felt that the national document was a recognised standard and promoted within the BTS guidance and therefore was the most appropriate to promote. It was noted that the asthma UK document does not include clear guidance regarding which patients should be issued with steroid cards. The group felt this section to be particularly useful and thus wished to retain this and add it to the formulary / link to the asthma guidelines. 10. Liothyronine for hypothyroidism Action: JS to update link in local asthma guidelines to the latest adult management plan JS to discuss with specialists the table of when to issue a steroid alert card AR to feedback to Mansfield and Ashfield CCG See item 5b also. Concerns were raised about the use of this medicine for nebulous indications possibly including subclinical hypothyroidism. It was requested that liothyronine be made grey (non-formulary). 11. Information sheet on misuse potential of pregabablin & gabapentin meeting dates Action: JS/LK to discuss with specialists the proposal to make liothyronine grey. JS/LK to take to APC TB introduced the document produced by the Nottinghamshire Prescription and Over-the-Counter Medicines Misuse and Dependence Working Group. The document was well received and thought to highlight an important issue locally. Only minor amendments were suggested. Action: AR/TB to take to APC Noted for information Action: JS/LK to arrange venues and send members dates 13. Any other None business 14. Date and time Thursday 11 th December 2014 Duncan Macmillan House. 2pm -5pm. of next meeting The meeting ended at 4:45 pm 5
Nottinghamshire Joint Formulary Group Meeting Minutes Thursday 9th June 2016, 2-5pm A01, Duncan Macmillan House
Nottinghamshire Joint Formulary Group Meeting Minutes Thursday 9th June 2016, 2-5pm A01, Duncan Macmillan House Present: Esther Gladman (EG) GP Prescribing Lead, Nottingham City CCG (chair); Daniel Shipley
More informationNottinghamshire Joint Formulary Group Meeting Minutes Thursday 11th June 2015, 2-5pm Room A01, Duncan Macmillan House
Nottinghamshire Joint Formulary Group Meeting Minutes Thursday 11th June 2015, 2-5pm Room A01, Duncan Macmillan House Present: Steve May (SM) Chief Pharmacist, SFHT (chair); James Sutton (JS) and Lynne
More informationMETHYLPHENIDATE AND ATOMOXETINE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER IN CHILDREN AND YOUNG PEOPLE
NOTTINGHAMSHIRE AREA PRESCRIBING COMMITTEE SHARED CARE PROTOCOL AGREEMENT METHYLPHENIDATE AND ATOMOXETINE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER IN CHILDREN AND YOUNG PEOPLE OBJECTIVES To
More informationNottinghamshire Joint Formulary Group Meeting Minutes Thursday 10 th August 2017, 2-5pm Boardroom, Duncan Macmillan House
Nottinghamshire Joint Formulary Group Meeting Minutes Thursday 10 th August 2017, 2-5pm Boardroom, Duncan Macmillan House Present: David Kellock (DK) Consultant, SFHFT(chair); Esther Gladman (EG) GP Prescribing
More informationAdult Neurodevelopmental Services. ADHD Shared Protocol
Adult Neurodevelopmental Services ADHD Shared Protocol Issue 1: April 2016 1 2 Adult Neurodevelopmental Service Shared Care Protocol for Adult Attention Deficit Hyperactivity Disorder (ADHD) 1. BACKGROUND
More informationSHARED CARE PROTOCOL FOR THE PRESCRIBING AND MONITORING OF MEDICINES FOR ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD)
SHARED CARE PROTOCOL FOR THE PRESCRIBING AND MONITORING OF MEDICINES FOR ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD) 1. Introduction This protocol describes how patients prescribed medicines for ADHD
More informationSHARED CARE GUIDELINE
SHARED CARE GUIDELINE Title: Shared Care Guideline for the prescribing and monitoring of Antipsychotics for the treatment of Schizophrenia and psychotic symptoms in children and adolescents Scope: Pennine
More informationIf a specialist asks a GP to prescribe ADHD medication in relation to this disease, the GP should reply to this request as soon as practicable.
Shared Care Protocol for the Methylphenidate and the Management of Attention Deficit Hyperactivity Disorder (ADHD) for children from 4 years up to 17 years and 364 days 1.0 INTRODUCTION The medical assessment
More informationNottinghamshire Joint Formulary Group Meeting Minutes Thursday 21 st June, 2-5pm Boardroom, Duncan Macmillan House
Nottinghamshire Joint Formulary Group Meeting Minutes Thursday 21 st June, 2-5pm Boardroom, Duncan Macmillan House Present: Steve Haigh (SH) MI Pharmacist, SFHFT(Chair); Tanya Behrendt (TB) Deputy AD Medicines
More informationFORMULARY UPDATES ABUHB s Drug Formulary is at:
Aneurin Bevan University Health Board Medicines & Therapeutics Committee PRESCRIBING enewsletter archive at: http://www.wales.nhs.uk/sites3/page.cfm?orgid=814&pid=48407 Dear Gwent Prescriber At its last
More informationSHARED CARE GUIDELINE
SHARED CARE GUIDELINE Methylphenidate in the treatment of Attention Deficit Hyperactivity Disorder in Children, Young People and Adults Implementation Date: June 2015 Review Date: June 2017 This guidance
More informationNorth of Tyne Area Prescribing Committee DECISION SUMMARY North of Tyne Area Prescribing Committee Summary of decisions made regarding new product requests considered at a meeting of the Committee on Tuesday
More informationSHARED CARE GUIDELINE
SHARED CARE GUIDELINE Shared Care Guideline for the prescribing and monitoring of antipsychotics for the treatment of Neurodevelopmental Disorders in children and adolescents. Scope: Version 1 Pennine
More informationGuidance on Safe Prescribing of Melatonin for Sleep Disorders in Children, Young People and Adults
Guidance on Safe Prescribing of Melatonin for Sleep Disorders in Children, Young People and Adults Ref: PHARM-0025-v3 Status: FINAL Document type: Guidelines Guidance on Safe Prescribing of Melatonin Page
More informationKiran Hewitt Katie Sims. Dr Alex Day. Reviewed By Ozma Tahir Lead Medicines Information and Clinical Economy Pharmacist, BHFT
Prescribing Arrangements for the use of methylphenidate, atomoxetine, lisdexamfetamine and amfetamine in adult ADHD (attention deficit hyperactivity disorder) in Berkshire For all referrals of adults with
More informationMinutes of Rotherham Medicines Optimisation Group (RMOG)
Minutes of Rotherham Medicines Optimisation Group (RMOG) Date/time: Venue: Chair: Minutes: Wednesday 4 th October, 1pm 3pm Pharmacy Seminar Room, A level, Rotherham Hospital Osman Chohan, Chief Pharmacist
More informationBenzodiazepines and Hypnotics
Benzodiazepines and Hypnotics Full Title of Guideline: Author (include email and role): Division & Speciality: Scope (Target audience, state if Trust wide): Review date (when this version goes out of date):
More informationMethylphenidate Shared Care Agreement For attention deficit hyperactivity disorder (ADHD) in adults Effective Shared Care Agreement
Methylphenidate Shared Care Agreement For attention deficit hyperactivity disorder (ADHD) in adults Effective Shared Care Agreement Section 1: Shared Care arrangements and responsibilities Section 1.1
More informationSeretide 250mcg/125mcg Evohaler switch to Fostair 100/6 MDI in COPD.
Seretide 250mcg/125mcg Evohaler switch to Fostair 100/6 MDI in COPD. Applies to HaRD CCG employed Pharmacists and Medicines Optimisation Technicians These protocols are produced by the NY&AWC MM team hosted
More informationShared Care Agreement for Donepezil
ESCA: for the treatment of Alzheimer s disease SECONDARY CARE SECTION TO BE COMPLETED BY INITIATING DOCTOR Patient s Name: Date of Birth: NHS Number: ESCA Date: One copy of information leaflet given to
More informationSHARED PRESCRIBING GUIDELINE
working in partnership with Kingston Richmond Wandsworth SHARED PRESCRIBING GUIDELINE Sutton & Merton Methylphenidate, Dexamfetamine and Atomoxetine for Attention Deficit Hyperactivity Disorder in patients
More informationPrescribing Framework for Galantamine in the Treatment and Management of Dementia
Hull & East Riding Prescribing Committee Prescribing Framework for Galantamine in the Treatment and Management of Dementia Patients Name:.. NHS Number: Patients Address:... (Use addressograph sticker)
More informationAppendix 4I - Melatonin Guidance for the treatment of sleep-wake cycle disorders in children
Appendix 4I - Melatonin Guidance for the treatment of sleep-wake cycle disorders in children Background Sleep disturbance in children with neurological or behavioural disorders is common and can be a major
More informationDocument Details. Patient Group Direction
Document Details Title Patient Group Direction (PGD) Salbutamol Aerosol Inhaler and salbutamol Nebulised Solution Trust Ref No 1569-34313 Local Ref (optional) Main points the document Treatment of acute
More informationSHARED CARE PRESCRIBING GUIDELINE
Approval date: September 2018. Document review date: September 2021 or sooner if evidence/practice changes g SHARED CARE PRESCRIBING GUIDELINE Methylphenidate, atomoxetine, lisdexamfetamine, dexamfetamine
More informationEFFECTIVE SHARED CARE AGREEMENT (ESCA)
WORKING IN PARTNERSHIP WITH EFFECTIVE SHARED CARE AGREEMENT (ESCA) DRUG NAME: ACETYLCHOLINESTERASE-INHIBITORS AND MEMANTINE INDICATION/S COVERED: Dementia in Alzheimers Disease Coastal West Sussex Traffic
More informationDocument Details. Ibuprofen 200mg tablets and Ibuprofen oral liquid 100mg in 5ml
Title Document Details Patient Group Direction (PGD) Ibuprofen 200mg tablets and Ibuprofen oral liquid 100mg in 5ml Trust Ref No 1445-36348 Local Ref (optional) Main points the document The treatment of
More informationSAFEGUARDING ANNUAL REPORT
SAFEGUARDING ANNUAL REPORT 1 APRIL 2017 31 MARCH 2018 A summary of key achievements and future plans for Mid Nottinghamshire and Greater Nottinghamshire CCGs to fulfil their duties to safeguard and promote
More informationAsacol / Mesalazine to Octasa Switch protocol
Asacol / Mesalazine to Octasa Switch protocol Applies to HaRD MMT Technicians, Pharmacists These protocols are produced by the NY&AWC MM team hosted by HaRD CCG for use by their employed MM team members.
More informationPrescribing Framework for Rivastigmine in the Treatment and Management of Dementia
Hull & East Riding Prescribing Committee Prescribing Framework for Rivastigmine in the Treatment and Management of Dementia Patients Name:.. NHS Number: Patients Address:... (Use addressograph sticker)
More informationpat hways Key therapeutic topic Published: 26 February 2016 nice.org.uk/guidance/ktt16
pat hways Anticoagulants, including non-vitamin K antagonist oral anticoagulants (NOACs) Key therapeutic topic Published: 26 February 2016 nice.org.uk/guidance/ktt16 Options for local implementation NICE
More informationIssue date September 2010 (Reviewed October 2013) Clinicians from Andrew Lang Centre, Mental. Specialist Pharmacist & Formulary Pharmacist
Title Document Type Issue no Shared care guidelines in the Treatment of Attention Deficit/ Hyperactivity Disorders Shared Care Guidelines and Information for GPs Clinical Governance Support Team Use Issue
More informationEAST LANCASHIRE HEALTH ECONOMY MEDICINES MANAGEMENT BOARD IN SEMINAR ROOM 6, LEARNING & DEVELOPMENT CENTRE, ROYAL BLACKBURN HOSPITAL
EAST LANCASHIRE HEALTH ECONOMY MEDICINES MANAGEMENT BOARD MINUTES OF THE MEETING HELD ON WEDNESDAY 15 th NOVEMBER 2017 AT 12.30pm IN SEMINAR ROOM 6, LEARNING & DEVELOPMENT CENTRE, ROYAL BLACKBURN HOSPITAL
More informationEssential Shared Care Agreement: Lithium
Ref No. E042 Essential Shared Care Agreement: Lithium Please complete the following details: Patient s name, address, date of birth Treatment (indication, dose regimen, brand name) Monitoring (proposed
More informationGreater Manchester Asthma Management Plan 2018 Inhaler therapy options for adult patients (18 and over) with asthma
Greater Manchester Asthma Management Plan 2018 Inhaler therapy options for adult patients (18 and over) with asthma Non-pharmacological options for ALL patients, consider at ALL stages Make sure diagnosis
More informationSOMERSET PRESCRIBING FORUM
SOMERSET PRESCRIBING FORUM Minutes of the meeting held at Wynford House, Yeovil, on Wednesday 14 November 2012 Present Position Initials Chair, Drug & Therapeutics Committee, Taunton & Somerset NHS Foundation
More information2017/2018 ADHD Guidelines: A Summary of Recommendations for Pharmacological Treatment From Selected Guidelines
2017/2018 ADHD Guidelines: A Summary of Recommendations for Pharmacological Treatment From Selected Guidelines Supporting patients throughout their lives Date of preparation: December 2018 Job code: C-ANPROM/INT//4324
More informationLMMG New Medicine Recommendation
LMMG New Medicine Recommendation Lisdexamfetamine (Elvanse ) for the treatment of ADHD in children and young adults LMMG Recommendation: Red (Restricted) Lisdexamfetamine (Elvanse ) is recommended for
More informationBuprenorphine used in the treatment of opioid dependence: availability and price
7 th floor Wellington House 133 155 Waterloo Road London SE1 8UG 24 October 2018 Gateway number: L2018-443 Dear Director of Public Health, Buprenorphine used in the treatment of opioid dependence: availability
More informationTHEOPHYLLINE WITH INHALED CORTICOSTEROIDS (TWICS) TRIAL SELF MANAGMENT / ACTION PLANS GENUAIR INHALERS: POTENTIAL SAFETY ISSUE
I S S U E 4 M A R C H / A R P I L 2 0 1 6 Endorsed December 2014 I N S I D E T H I S I S S U E : Theophylline with Inhaled Corticosteroids (TWICS) Trial Genuair Inhaler: Potential Safety Issue 1 Self Management
More informationBournemouth, Dorset and Poole Prescribing Forum
SHARED CARE GUIDELINE FOR THE USE OF ATOMOXETINE IN ADULTS WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER INDICATION Atomoxetine is a non-stimulant non-amphetamine inhibitor of noradrenaline reuptake. It
More informationCardiff & Vale (C&V) UHB Corporate Medicines Management Group (c MMG) SHARED CARE DRUG: LISDEXAMFETAMINE PROTOCOL NUMBER: CV 57
Cardiff & Vale (C&V) UHB Corporate Medicines Management Group (c MMG) SHARED CARE DRUG: LISDEXAMFETAMINE PROTOCOL NUMBER: CV 57 INDICATION: Attention deficit hyperactivity disorder (ADHD) as part of a
More informationGREATER MANCHESTER INTERFACE PRESCRIBING GROUP
GREATER MANCHESTER INTERFACE PRESCRIBING GROUP On behalf of the GREATER MANCHESTER MEDICINES MANAGEMENT GROUP SHARED CARE GUIDELINE FOR THE PRESCRIBING OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)
More informationTechnology appraisal guidance Published: 28 November 2018 nice.org.uk/guidance/ta547
Tofacitinib for moderately to severelyerely active ulcerative colitis Technology appraisal guidance Published: 28 November 2018 nice.org.uk/guidance/ta547 NICE 2019. All rights reserved. Subject to Notice
More informationDocument Title Pharmacological Management of Generalised Anxiety Disorder
Document Title Pharmacological Management of Generalised Anxiety Disorder Document Description Document Type Policy Service Application Trust Wide Version 1.1 Policy Reference no. POL 201 Lead Author(s)
More informationThey are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:
Ongoing care for adults with psychosis or schizophrenia bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to be used online. They are updated regularly
More informationGREAT WESTERN HOSPITALS NHS FOUNDATION TRUST
Attendees: Dr Ravi Chinthapalli (RC) (chair) Katherine Watkinson () (mins) Dr Rachel Hobson (RH) Paul Clarke (PC) Lisa King (LK) Formulary Working Group 17 th October 2013 1400 1510 Liden Meeting Room,
More informationDERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) Minutes of the meeting held on Tuesday 8 May 2012
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) Minutes of the meeting held on Tuesday 8 May 2012 Summary Points Traffic lights Drug Pro D3 Fultium Rifaxamin for traveller s diarrhoea Rifaxamin for
More informationGREAT WESTERN HOSPITALS NHS FOUNDATION TRUST
The 3T s Formulary NHS Swindon NHS Wiltshire Great Western Hospitals NHS Foundation Trust (In collaboration with Avon and Wiltshire Mental Health Partnership and Oxford Health NHS Foundation Trust) Attendees:
More informationMeeting of the Formulary Working Group (FWG) Held on Friday 20th May 2016, Board room 1, Anglesey House, Rugeley
Meeting of the Formulary Working Group (FWG) Held on Friday 20th May 2016, Board room 1, Anglesey House, Rugeley 29/05/2015 31/07/2015 18/09/2015 22/01/2016 20/05/2016 Samantha Buckingham Pharmaceutical
More informationUSE OF UNLICENSED MEDICINES AND OFF-LABEL MEDICINES WHERE A LICENSED MEDICINE IS AVAILABLE
NHS Scotland Directors of Pharmacy and Scottish Association of Medical Directors USE OF UNLICENSED MEDICINES AND OFF-LABEL MEDICINES WHERE A LICENSED MEDICINE IS AVAILABLE CONSENSUS STATEMENT This consensus
More informationDERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) Minutes of the meeting held on Tuesday 10 th May 2011
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) Minutes of the meeting held on Tuesday 10 th May 2011 Summary Points Shared care updates Acetylcholinesterase inhibitors Modafanil for narcolepsy Riluzole
More informationDERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) Minutes of the meeting held on Tuesday 11 December 2012 CONFIRMED MINUTES
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) Minutes of the meeting held on Tuesday 11 December 2012 CONFIRMED MINUTES Summary Points Traffic lights Drug Ivabradine for heart failure Denosumab Fluoxetine
More informationrequesting information regarding prescribing incentive schemes in Canterbury and Coastal Clinical Commissioning Group
requesting information regarding prescribing incentive schemes in Canterbury and Coastal Clinical Commissioning Group Canterbury and Coastal Clinical Consortium Group Medicine Management plans 2013/14
More informationFrimley Health Area Prescribing Committee
Frimley Health Area Prescribing Committee Frimley Health NHS Foundation Trust North East Hampshire and Farnham CCG East Berkshire CCG Surrey Heath CCG Buckinghamshire CCG SHARED CARE Guideline Amber Traffic
More informationSHARED CARE GUIDELINE
SHARED CARE GUIDELINE Title: Lithium Treatment in Adults aged 18-65 years Scope: Pennine Care NHS Foundation Trust NHS Bury NHS Oldham NHS Heywood, Middleton and Rochdale NHS Stockport NHS Tameside & Glossop
More informationClinical. High Dose Antipsychotic Prescribing Procedures. Document Control Summary. Contents
Clinical High Dose Antipsychotic Prescribing Procedures Document Control Summary Status: Version: Author/Owner/Title: Approved by: Ratified: Related Trust Strategy and/or Strategic Aims Implementation
More informationDERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) Minutes of the meeting held on Tuesday, 9 th August 2011
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) Minutes of the meeting held on Tuesday, 9 th August 2011 Summary Points Guidelines ratified Treatment guideline for glaucoma Oral Nutrition Supplements
More informationPRESCRIBING INCENTIVE SCHEME 2018/19
PRESCRIBING INCENTIVE SCHEME 2018/19 Summary Harrogate and Rural District CCG is continuing to offer a prescribing incentive scheme to all its member NHS GP practices as encouragement and reward to improve
More informationMinutes. 20 Th January 2015, 12:30-2:30 pm Pharmacy Dept. CMFT
Minutes 20 Th January 2015, 12:30-2:30 pm Pharmacy Dept. CMFT Present: Elizabeth Arkell (EA), Associate Director of Pharmacy, UHSM Foundation Trust Jennifer Bartlett (JB) Senior Medicines Management Pharmacist
More informationMetformin MR to low cost branded generic (Sukkarto SR) Switch Protocol
Metformin MR to low cost branded generic (Sukkarto SR) Switch Protocol Applies to HaRD CCG employed Pharmacists and Medicines Optimisation Technicians. These protocols are produced by the NY&AWC MM team
More informationSHARED CARE GUIDELINE
SHARED CARE GUIDELINE Shared Care Guideline for the treatment of Tourette s Syndrome and other tic disorders in children and adolescents. Scope: Version: Pennine Care NHS Foundation Trust NHS Bury NHS
More informationNikki Mallinder on behalf of Linda Honey. Karen Thorburn Date: 04/10/18
Agenda item: 7 ii Paper no: PCCC ic 20-18 Title of Report: Status: Committee: Venue: Update to the Attention Deficit Hyperactivity Disorder (ADHD) in Childhood) 12 monthly physical medication monitoring
More informationPATIENT GROUP DIRECTION PROCEDURE
PATIENT GROUP DIRECTION PROCEDURE Date approved 2 October 2015 Version 3 Approved by Yvette Oade, Chief Medical Officer Procedure Lead Clinical Governance Lead - Medicines Management Procedure Author Karen
More informationPrescribing of high-dose and combined antipsychotics for patients on forensic wards.
POMH-UK Topic 3 baseline May 2007 Prescribing of high-dose and combined antipsychotics for patients on forensic wards. Prepared by the Prescribing Observatory for Mental Health (POMH-UK) for member Healthcare
More informationAripiprazole Long-Acting Injection (Abilify Maintena ) Guidelines for Prescribing and Administration (Version 3 August 2014)
1. Key Points. Aripiprazole Long-Acting Injection (Abilify Maintena ) Guidelines for Prescribing and Administration (Version 3 August 2014) 1.1 Aripiprazole long acting injection (LAI) is licensed / indicated
More informationPatient Group Directions (PGDs)
Patient Group Directions (PGDs) Document level: Trustwide (TW) Code: MP2 Issue number: 4 Lead executive Authors details Type of document Target audience Document purpose Medical Director Senior Clinical
More informationDERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) Minutes of the meeting held on Tuesday 10 July 2012 CONFIRMED MINUTES
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) Minutes of the meeting held on Tuesday 10 July 2012 CONFIRMED MINUTES Summary Points Traffic lights Drug Rivaroxaban Dabigatran Drugs of Limited Clinical
More informationLondon Medicines Information Service
London Medicines Information Service Extended-release methylphenidate a review of the pharmacokinetic profiles available March 2018 First authored by Martin Bradley (martin.bradley@gstt.nhs.uk) May 2016
More informationCHARM ASTHMA TREATMENT GUIDELINE
NHS City and Hackney Prescribing Guidelines Adults ( 12 years of age) CHARM ASTHMA TREATMENT GUIDELINE Written by: Hetal Dhruve (Specialist Respiratory Pharmacist, City and Hackney CCG) Checked by: Prof
More informationDERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) Minutes of the meeting held on Tuesday 11 th February 2014 CONFIRMED MINUTES
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) Minutes of the meeting held on Tuesday 11 th February 2014 CONFIRMED MINUTES Summary Points Traffic lights Drug Decision Tramacet Amorolfine Minocycline
More informationDRUG: Introduction. `Shared Care Guidelines. They can also be used long term for chronic pulmonary Pseudomonas aeruginosa infection.
`Shared Care Guidelines DRUG: Introduction Inhaled antibiotics (Adults and Paediatrics) in Cystic Fibrosis. EXISTING ESTABLISHED PATIENTS ONLY Colistimethate (Colomycin, Promixin ) Tobramycin (Tobi Bramitob
More informationPaliperidone Palmitate 3-monthly Long-Acting Injection (Trevicta ) Guidelines for Prescribing and Administration (Version 1 October 2016)
Paliperidone Palmitate 3-monthly Long-Acting Injection (Trevicta ) Guidelines for Prescribing and Administration (Version 1 October 2016) 1. Key Points 1.1 Paliperidone palmitate 3-monthly long-acting
More informationESCA: Cinacalcet (Mimpara )
ESCA: Cinacalcet (Mimpara ) Effective Shared Care Agreement for the Treatment of Primary hyperparathyroidism when parathyroidectomy is contraindicated or not clinically appropriate. Specialist details
More informationPrescription. Information Services. Gateway: 01/NHSBSA/RxS/01/2017
& Prescription Information Services Gateway: 01/NHSBSA/RxS/01/2017 3 Welcome to the April 2017 issue of Hints & Tips! Contents If you ve got a hint or tip that you would like us to write about in a future
More informationBournemouth, Dorset and Poole Prescribing Forum
SHARED CARE GUIDELINES FOR PRESCRIBING OF METHYLPHENIDATE IN ATTENTION DEFICIT HYPERACTIVITY DISORDER IN CHILDREN INDICATION Methylphenidate is generally regarded as a first line choice of treatment for
More informationInclude patients: with a confirmed diagnosis of asthma who have been free of asthma symptoms for 3 months or more.
Corby Clinical Commissioning Group Kettering General Hospital NHS Trust Nene Clinical Commissioning Group rthampton General Hospital NHS Trust rthamptonshire Healthcare Foundation Trust Stepping down asthma
More informationLiothyronine for treatment resistant depression
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) SHARED CARE AGREEMENT FRAMEWORK Liothyronine for treatment resistant depression 1. REFERRAL CRITERIA Shared Care is only appropriate if it provides the
More informationfor adults engaged with the Family Wellbeing Service Isle of Wight In Community Pharmacy for Isle of Wight Public Health Commissioned Services
The supply of Champix (Varenicline) Tablets 500mcg and 1mg by registered community pharmacists for smoking cessation / management of nicotine withdrawal for adults engaged with the Family Wellbeing Service
More informationMERSEY CARE NHS TRUST HOW WE MANAGE MEDICINES. MM11 - High-Dose Antipsychotic Use Guidelines (local guideline) KEY ISSUES
MERSEY CARE NHS TRUST HOW WE MANAGE MEDICINES MM11 - High-Dose Antipsychotic Use Guidelines (local guideline) Medicines Management Services aim to ensure that (i) Service users receive their medicines
More informationPeople living well with Dementia in the East Midlands: Improving the Quality of Care in Acute Hospitals
PROJECT INITIATION DOCUMENT We re in it together People living well with Dementia in the East Midlands: Improving the Quality of Care in Acute Hospitals Version: 1.1 Date: February 2011 Authors: Jillian
More informationGMMMG Interface Prescribing Subgroup. Minutes. 14 th January 2016, 1pm-3pm Croft Shifa Health Centre, Belfield Road, Rochdale
GMMMG Interface Prescribing Subgroup Minutes 14 th January 2016, 1pm-3pm Croft Shifa Health Centre, Belfield Road, Rochdale Present: Dr Richard Darling (RD) General Practitioner, Heywood, Middleton and
More informationPatient Group Directions Policy
Patient Group Directions Policy Category: Summary: Equality Analysis undertaken: Valid From: Date of Next Review: Approval Date/ Via: Distribution: Related Documents: Author(s): Further Information: This
More informationTopic proposal. 1. What is the problem/need for a guideline/clinical scenario?
Topic proposal I understand that this proposal will be retained by the Programme Lead and be made available on the website for time period that the proposal is being considered. Only proposals with a completed
More informationPrescribing of high-dose and combination antipsychotics on adult acute and intensive care wards: Clinical introduction, methodology and glossary.
POMH-UK Topic 1 report 1b Prescribing of high-dose and combination antipsychotics on adult : Clinical introduction, methodology and glossary. March 2007 Prepared by the Prescribing Observatory for Mental
More informationClinical guideline Published: 24 September 2008 nice.org.uk/guidance/cg72
Attention deficit hyperactivity disorder: diagnosis and management Clinical guideline Published: 24 September 2008 nice.org.uk/guidance/cg72 NICE 2018. All rights reserved. Subject to Notice of rights
More informationEssential Shared Care Agreement: Melatonin (Circadin, Bio-Melatonin)
Ref No: E056 Essential Shared Care Agreement: Melatonin (Circadin, Bio-Melatonin) Please complete the following details: Patient s name, address, date of birth, and either complete when the consultant
More informationDocument Title Antipsychotics Prescribing Guidelines for Schizophrenia
Document Title Antipsychotics Prescribing Guidelines for Schizophrenia Document Description Document Type Prescribing Guidance Service Application Medicines Management Version 1.0 Policy Reference no.
More informationNHS Kent and Medway Medicines Management. Dronedarone (Multaq ) Shared Care Guideline For Prescribing
NHS Kent and Medway Medicines Management Dronedarone (Multaq ) Shared Care Guideline For Prescribing Issue No: 2 Review Date (If Applicable): Accountable Officer: Heather Lucas Contact Details: 01233 618158
More informationMinutes of Medicines Commissioning Committee Meeting Wednesday 12 th April pm, West Offices, York
1. Apologies / Attendance Minutes of Medicines Commissioning Committee Meeting Wednesday 12 th April 2017 9.30-12pm, West Offices, York Strategic Lead Pharmacist- T Chair & Vale of York CCG Pharmacist
More informationVolume 7; Number 12 July 2013
Greater East Midlands Commissioning Support Unit in association with Lincolnshire Clinical Commissioning Groups, Lincolnshire Community Health Services, United Lincolnshire Hospitals Trust and Lincolnshire
More information. AREAS OF RESPONSIBILITY FOR SHARED CARE
SHARED CARE GUIDELINE FOR RILUZOLE IN THE MANAGEMENT OF MOTOR NEURONE DISEASE (MND) SPECIFICALLY AMYOTROPHIC LATERAL SCLEROSIS (ALS) INDICATION This shared care guideline has been prepared to support the
More informationGuideline Ulcerative colitis: management
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Guideline Ulcerative colitis: management Draft for consultation, December 0 This guideline covers the care and treatment of adults, children and young
More information1.1. This guideline applies to medical, nursing and pharmacy staff in the safe and appropriate prescription and administration of acamprosate.
SHARED CARE GUIDELINE FOR ACAMPROSATE 1. Aim/Purpose of this Guideline 1.1. This guideline applies to medical, nursing and pharmacy staff in the safe and appropriate prescription and administration of
More informationCosting statement. Implementing NICE guidance. January NICE clinical guideline 137
The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care (partial update of NICE clinical guideline 20) Costing statement Implementing NICE guidance
More informationEvidence review for Surrey Prescribing Clinical Network SUMMARY
East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG, Surrey Heath CCG, Crawley CCG, Horsham & Mid-Sussex CCG Evidence review for Surrey Prescribing Clinical Network Medicine
More informationDORSET MEDICINES ADVISORY GROUP Recommendation Summary
DORSET MEDICINES ADVISORY GROUP Recommendation Summary Formerly the Bournemouth, Dorset and Poole Health Technologies Forum, DMAG represents the four provider Trusts and GPs within the Clinical Commissioning
More informationEAST LANCASHIRE HEALTH ECONOMY MEDICINES MANAGEMENT BOARD IN SEMINAR ROOM 6, LEARNING & DEVELOPMENT CENTRE, ROYAL BLACKBURN HOSPITAL
EAST LANCASHIRE HEALTH ECONOMY MEDICINES MANAGEMENT BOARD MINUTES OF THE MEETING HELD ON WEDNESDAY 15 th JUNE 2016 AT 12.30pm IN SEMINAR ROOM 6, LEARNING & DEVELOPMENT CENTRE, ROYAL BLACKBURN HOSPITAL
More informationPatient and Public Reference Group for Medicines ADTC Sub-group NHS Tayside 17 th February 2015
Patient and Public Reference Group for Medicines ADTC Sub-group NHS Tayside 17 th February 2015 Claire James, Senior Pharmacist Clinical Effectiveness, Ninewells Hospital Aims To increase awareness and
More information